# GLP-1 Drugs and Addiction: A Huge Signal, and a Trial That Missed

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/glp1-and-substance-use

> A 524,817-person cohort found fewer new substance use disorders of every kind measured. A randomized trial in people who smoke then missed both its primary endpoints. Both landed in 2026.

## Key points

- 524,817 veterans: every substance use disorder reduced, HR 0.75 (opioid) to 0.86 (cannabis).
- Pre-existing SUD: substance-related mortality HR 0.50, overdose 0.61, ED visits 0.69.
- The randomized smoking trial MISSED both co-primary endpoints, and it randomized 24 people.
- Suicidal ideation HR 0.75, agreeing with the separate evidence behind the February 2026 label change.

Two studies landed in 2026 and they point different ways. A cohort of **524,817** US veterans found people starting a GLP-1 developed fewer new substance use disorders of every kind measured (alcohol, cannabis, cocaine, nicotine, [opioids](https://glpwatchdog.org/research/glp1-and-opioid-use-disorder)) than people starting a comparable drug.[1] A randomized trial of semaglutide in people who smoke daily then **missed both its primary endpoints**: craving fell and weight fell, but resistance to smoking and cigarettes per day did not move significantly.[2] That trial randomized 24 people. Both results need to be read together.

## What the cohort found

The design is better than most observational work. Drawing on 606,434 US veterans with type 2 diabetes, the researchers emulated eight parallel target trials, comparing people who started a GLP-1 against people who started an SGLT-2 inhibitor. Comparing against an active drug rather than against nobody controls for the fact that people who get prescribed something differ from people who get prescribed nothing.[1]

*New substance use disorders over up to three years, GLP-1 initiators against SGLT-2 inhibitor initiators. Hazard ratios below 1 favor the GLP-1.*

| Disorder | Hazard ratio (95% CI) |
| --- | --- |
| Opioid use | 0.75 (0.67–0.85) |
| Cocaine use | 0.80 (0.72–0.88) |
| Nicotine use | 0.80 (0.74–0.87) |
| Alcohol use | 0.82 (0.78–0.85) |
| Cannabis use | 0.86 (0.81–0.90) |
| **All substance use disorders combined** | **0.86 (0.83–0.88)** |

Among veterans who already had a substance use disorder, the outcomes that matter clinically moved too: fewer emergency department visits (0.69), fewer hospital admissions (0.74), fewer overdoses (0.61), and substance-related mortality at **0.50**, or half.[1]

> **Read the absolute numbers alongside the ratios.** The composite works out to about 6.6 fewer diagnoses per 1,000 people over three years. A hazard ratio of 0.86 is a real effect, but on its own it does not transform anyone’s life expectancy. Both numbers describe the same finding; the ratio is the one that gets quoted.

## What the randomized trial found

Also in 2026, a phase 2a trial gave semaglutide or placebo for nine weeks to adults smoking at least five cigarettes a day, with laboratory sessions measuring how well they resisted smoking and how much they smoked when they could.[2]

Neither co-primary outcome reached significance. Smoking resistance came in at β 0.16 (95% CI −0.07 to 0.40, P = .16); number of cigarettes at β −0.08 (95% CI −0.25 to 0.08, P = .30).[2] What did move was *craving* for cigarettes, which fell significantly, along with body weight.

> Wanting a cigarette less is not the same as smoking fewer of them, and this trial separated the two. (What nicotine itself does to weight is set out in [does vaping or nicotine cause weight loss](https://glpwatchdog.org/research/does-vaping-or-nicotine-cause-weight-loss).)

> **It randomized 24 people.** The authors did not hide this. It is a phase 2a laboratory study, designed to detect mechanism rather than to establish cessation, and their own conclusion calls for larger trials. But the null results are weakly powered, and a supplementary analysis that *did* reach significance should be read as a hypothesis rather than a finding. Small trials produce both kinds of error.

## Why the two disagree, and which to trust for what

This is the same pattern our [alcohol article](https://glpwatchdog.org/research/alcohol-and-glp1s) documents, in a different substance and by the same research group: a large observational signal, and randomized tests that shrink or vanish when they measure behavior rather than desire.

The most likely explanation is not that one study is wrong. Observational data compare people who took a drug against people who did not, and no weighting fully removes the differences between those groups. Someone prescribed a GLP-1 is engaged with healthcare in ways that themselves predict fewer substance problems. Randomized trials remove that, and pay for it in size and duration. Nine weeks in 24 people is not a fair test of whether someone quits smoking.

The signal is real enough to be worth a properly powered trial, and there is not yet convincing evidence that these drugs help anyone quit anything. Those two statements are compatible.

## One result that checks out against something else

Among veterans with a pre-existing substance use disorder, suicidal ideation or attempt came in at a hazard ratio of **0.75** (0.67–0.83).[1] That points the same way as the evidence behind the removal of the suicidality warning from these labels in February 2026, which we cover in [the suicidality article](https://glpwatchdog.org/research/glp1-suicidal-ideation-what-happened). It comes from an entirely separate dataset and population.

Two independent bodies of evidence agreeing is worth more than either alone. It is still observational, and it is still in a population that is 90%-odd male veterans with type 2 diabetes.

## Smoking: five findings from eighty-four people

A pilot trial randomized 84 smokers with prediabetes or excess weight to exenatide or placebo, everyone also receiving a nicotine patch and brief counseling, with biologically confirmed abstinence at six weeks as the outcome. The drug arm did better. A follow-up analysis then asked *who* it worked for, and reported five moderators.[4] A larger trial has since tested the question head-on and found nothing; see [GLP-1s and quitting smoking](https://glpwatchdog.org/research/glp1-and-quitting-smoking) for that evidence and its 12-month follow-up.

*Reported moderators of exenatide’s effect. PP is posterior probability that an effect exists; the study’s threshold for reporting was 75%.[4]*

| Stronger effect in… | Posterior probability |
| --- | --- |
| People smoking more than 20 cigarettes a day | 81.7% |
| People *without* prediabetes | 76.0% |
| People *without* obesity | 94.4% |
| People with no or minimal depression symptoms | 91.2% |
| Carriers of one *CHRNA* rs16969968 genotype | 88.6% |

> **Read the threshold before the findings.** These are Bayesian posterior probabilities, not P values, and the bar for reporting was 75%. A result could therefore be included while carrying close to a one-in-four chance that no effect exists at all. That is an exploratory standard, appropriate for generating hypotheses and much weaker than the significance testing most readers will assume.

Now look at rows two and three. The trial *enrolled* smokers with prediabetes and/or excess weight, yet reports the drug working best in participants who had neither. When five subgroups are carved out of 84 people and the treatment looks most effective in the one least like the eligibility criteria, suspect noise before biology.

The genetic moderator deserves the same caution as every other pharmacogenomic subgroup in this field. Real associations do exist, and their effects are small (see [the genetics are real, and small](https://glpwatchdog.org/research/the-genetics-are-real-and-small)). A genotype effect found in a fraction of 84 people is a long way short of that.

What survives is the parent trial’s own result: adding a GLP-1 to a nicotine patch improved short-term abstinence in a pilot. The authors ask for larger prospective studies, which is the right request.

## A larger emulation, and the split within the class

A 2026 analysis went further, emulating four separate trials inside a records network covering more than 120 million patients. Adults with type 2 diabetes and no prior alcohol-use disorder starting tirzepatide, semaglutide, liraglutide or dulaglutide were each matched one-to-one against patients starting a DPP-4 inhibitor, and followed 18 months for a first diagnosis.[3]

*Incident alcohol-use disorder against DPP-4 inhibitors, after propensity matching.*

| Drug | Matched pairs | Hazard ratio (95% CI) |
| --- | --- | --- |
| Tirzepatide | 7,165 | **0.47 (0.29–0.75)** |
| Semaglutide | 20,198 | **0.68 (0.52–0.89)** |
| Liraglutide | 6,565 | Not significant |
| Dulaglutide | 19,061 | Not significant |

Head to head, tirzepatide beat liraglutide directly (0.47, 0.24–0.92). The split is the interesting part: the two newer, more potent agents show the effect and the two older ones do not, in the same drug class.

> **That pattern has at least two explanations and the study cannot separate them.** It could be dose or potency (more receptor activation, more effect on the reward pathways implicated here). Or it could be who takes what: tirzepatide and semaglutide are prescribed in a different era, to different patients, for different reasons, than liraglutide and dulaglutide. Propensity matching handles what is recorded and not what is not.

One more limit: the outcome is a *diagnosis code*. Someone has to seek care, and a clinician has to record alcohol-use disorder. That measures diagnosis rather than drinking, and it under-counts in both arms by an unknown amount. The authors conclude that randomized evidence for this indication is now appropriate, and that is the right conclusion.

## Frequently asked questions

### Do GLP-1 drugs help you quit smoking?

Not on current evidence. The randomized trial of semaglutide in people who smoke daily missed both its co-primary endpoints: neither resistance to smoking nor cigarettes per day changed significantly. Craving did fall, and so did weight. That trial randomized 24 people, so its null results are weakly powered too. A pilot of 84 smokers found exenatide added to a nicotine patch improved abstinence at six weeks, but a larger trial, of dulaglutide added to varenicline, found no benefit.

### What did the veterans study show?

Among 524,817 people with type 2 diabetes, those starting a GLP-1 developed fewer new substance use disorders than those starting an SGLT-2 inhibitor. Hazard ratios ran from 0.75 for opioid use to 0.86 for cannabis, with 0.86 for all combined. In absolute terms that is roughly 6.6 fewer diagnoses per 1,000 people over three years.

### Why do the cohort and the trial disagree?

They are answering slightly different questions with different weaknesses. Observational data cannot fully separate the drug from the kind of person who gets prescribed it. Randomized trials can, but this one ran nine weeks in 24 people, which is not a fair test of whether someone quits. The signal justifies a properly powered trial; it is not itself evidence of benefit.

### Should someone take a GLP-1 for addiction?

No GLP-1 is approved for any substance use disorder, and the randomized evidence on behavior is null or absent. Substance use disorders have treatments that are approved and tested in far larger numbers, and a clinician can set those out.

### Does this affect the suicide risk question?

It points the same way. Among veterans with a pre-existing substance use disorder, suicidal ideation or attempt came in at a hazard ratio of 0.75. That is consistent with the evidence behind the removal of the suicidality warning from these labels in February 2026, and it comes from an entirely separate dataset.

## References

1. Cai M, Choi T, Xie Y, Al-Aly Z. Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. BMJ. 2026. PMID: 41781010. https://pubmed.ncbi.nlm.nih.gov/41781010/
2. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial. JAMA Network Open. 2026. PMID: 42189538. https://pubmed.ncbi.nlm.nih.gov/42189538/
3. Henney AE, Riley DR, Heague M, et al. Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach. Diabetes, Obesity and Metabolism. 2026. PMID: 41058240. https://pubmed.ncbi.nlm.nih.gov/41058240/
4. Yammine L, de Dios C, Suchting R, et al. Exploring Predictors of Treatment Response to GLP-1 Receptor Agonists for Smoking Cessation. Nicotine & Tobacco Research. 2025. PMID: 39780397. https://pubmed.ncbi.nlm.nih.gov/39780397/

---

Cite as: GLP Watchdog, Nora Bissett, "GLP-1 Drugs and Addiction: A Huge Signal, and a Trial That Missed", published 2026-08-19, updated 2026-10-27. https://glpwatchdog.org/research/glp1-and-substance-use

Canonical HTML page: https://glpwatchdog.org/research/glp1-and-substance-use

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
